New Blood Tests Show Promise in Early Alzheimer’s Detection

Recent advancements in Alzheimer’s research indicate that blood tests may soon serve as effective early warning systems for the disease. Current studies suggest that tracking changes in specific protein biomarkers over time may provide more accurate insights than relying on a single test result.

One significant study presented at the Radiological Society of North America’s annual meeting highlighted that obesity can obscure signs of Alzheimer’s. Specifically, it can dilute proteins linked to the disease, rendering one-time blood tests less reliable. Furthermore, another study discovered that individuals who expressed concerns about their memory, yet performed well on cognitive assessments, exhibited a marked increase in Alzheimer’s-related proteins over five years if their spinal fluid showed early signs of the disease. This suggests that abnormal indicators might develop even when initial tests appear normal.

The developments in blood-based testing for Alzheimer’s reflect a broader shift in diagnostic capabilities. As Cyrus A. Raji, a neuroradiologist at Washington University School of Medicine, noted, “Twenty years ago, when I started medical school, we could only diagnose Alzheimer’s at autopsy. This has revolutionized the field.”

Advancements in Detection Methods

Traditionally, Alzheimer’s diagnosis has relied on brain scans or spinal taps, which can be costly and difficult to access. For example, during a PET scan, doctors use a radioactive tracer to visualize amyloid proteins associated with cognitive decline. Abnormal amyloid buildup can lead to changes in tau proteins, which disrupt neuronal communication and contribute to memory loss. These diagnostic methods often occur in later stages of cognitive decline, limiting early intervention opportunities.

In a significant breakthrough, the FDA has recently approved two blood tests that detect Alzheimer’s-related biomarkers. Sheena Aurora, a neurologist and vice president of medical affairs at the Alzheimer’s Association, explained that one test serves as a “rule-out” tool, helping primary care providers determine when symptoms are likely due to causes other than Alzheimer’s. The second test, intended for specialists, indicates a stronger likelihood of Alzheimer’s-linked proteins in the brain.

These tests are meant to complement existing diagnostic measures, including family history, cognitive screenings, and imaging. They are not designed for general screening but are recommended for patients with observable signs of mild cognitive impairment.

Challenges and Considerations

Despite the potential of these blood tests, clinicians emphasize caution. Researchers have identified chronic diseases, particularly kidney dysfunction, as factors that can compromise test accuracy. Findings indicate that about one-third of older adults with mild kidney conditions may receive unreliable results. Corey Bolton, a clinical neuropsychologist at Vanderbilt University Medical Center, noted that certain biomarkers, such as neurofilament light chain, lose their efficacy in patients with stage three kidney disease.

The prevalence of chronic kidney disease among older adults—estimated at roughly 34% by the Centers for Disease Control and Prevention—highlights the need for a nuanced understanding of how these conditions can affect blood test results. Additionally, researchers advocate for further studies that include diverse populations, as most current biomarker validation studies predominantly involve homogeneous groups.

In a separate longitudinal study, researchers monitored 298 individuals who reported memory concerns but scored normally on cognitive tests over five years. They measured Alzheimer’s-related proteins in the blood at two-year intervals and found that those with a significant rise in these proteins were more likely to experience cognitive decline. About 20% of participants initially showing normal biomarker levels later developed abnormal ones.

The ongoing research underscores the importance of using multiple blood tests over time to create a comprehensive picture of an individual’s cognitive health. A single test can provide only a snapshot, whereas a series of tests can capture the progression of Alzheimer’s-related changes.

The future of Alzheimer’s detection lies in the potential for blood-based biomarkers to provide a less invasive means of monitoring changes in the brain. As Raji stated, “If we can identify individuals who have Alzheimer’s disease before they have dementia, we can be more successful at applying earlier treatments.” This approach could significantly improve treatment outcomes and expand access to effective diagnostics for millions of individuals.